Table 1.
Patient characteristics
| No. (%) | Patients completed genomic profiling (n = 1166) | Patients with potentially actionable alterations (n = 781) | P value |
|---|---|---|---|
| Median age (range) | 59 (18–92) | 57 (18–92) | 0.034 |
| Sex | 0.010 | ||
| Male | 696 (60) | 420 (54) | |
| Female | 470 (40) | 361 (46) | |
| ECOG PS | 0.613 | ||
| 0 | 304 (26) | 207 (27) | |
| 1 | 799 (69) | 524 (67) | |
| 2 | 63 (5) | 50 (6) | |
| Histology | < 0.001 | ||
| LUAD | 901 (77) | 681 (87) | |
| LUSC | 108 (9) | 46 (6) | |
| Othersa | 157 (13) | 54 (7) | |
| Smoking status | 0.002 | ||
| Never | 684 (59) | 495 (63) | |
| Former/current | 391 (34) | 207 (27) | |
| Unknown | 91 (8) | 79 (10) | |
| Disease stage | < 0.001 | ||
| III | 107 (9) | 32 (4) | |
| IV | 1059 (91) | 749 (96) | |
| Number of prior therapies | < 0.001 | ||
| Median (range) | 0 (0–12) | 1 (0–8) | |
| 0 | 657 (56) | 230 (29) | |
| 1 | 204 (17) | 274 (35) | |
| ≥2 | 305 (26) | 277 (36) | |
Abbreviations: ECOG PS, the Eastern Cooperative Oncology Group performance status; LUAD, lung adenocarcinoma; LUSC, lung squamous carcinoma
aOthers include large cell neuroendocrine carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma, mucoepidermoid carcinoma, lymphoepithelioma-like carcinoma, and low differentiated tumor